Archivio istituzionale della ricerca dell'Università degli Studi di Palermo
IRIS è il sistema di gestione integrata dei dati della ricerca (persone, pubblicazioni, progetti, attività) adottato dall’Università di Palermo, e ha lo scopo di raccogliere, conservare, documentare, e diffondere ad accesso aperto le informazioni relative alla produzione scientifica degli autori afferenti all’Ateneo.
EnglishThe world is facing a new pandemic caused by a novel beta coronavirus (COVID 19), which causes severe respiratory coronavirus syndrome (SARS-CoV-2). Unfortunately, there are currently no US Food and Drug Administration (FDA) approved medications for the treatment of COVID-19 patients. High mortality rates in frail patients is a notable feature of the virus registered since the onset of COVID-19 pandemic. Above all, elderly patients or those with underlying chronic illnesses and compromised immune system are most at risk (1). Thus, the consideration is that the possible coexistence, in the same individual, of a cancer diagnosis and a COVID-19 infection could generate a synergistic negative prognostic effect.
Brunetti O., Derakhshani A., Baradaran B., Galvano A., Russo A., & Silvestris N. (2020). COVID-19 Infection in Cancer Patients: How Can Oncologists Deal With These Patients?. FRONTIERS IN ONCOLOGY, 10.
| Data di pubblicazione: | 2020 | |
| Titolo: | COVID-19 Infection in Cancer Patients: How Can Oncologists Deal With These Patients? | |
| Autori: | ||
| Citazione: | Brunetti O., Derakhshani A., Baradaran B., Galvano A., Russo A., & Silvestris N. (2020). COVID-19 Infection in Cancer Patients: How Can Oncologists Deal With These Patients?. FRONTIERS IN ONCOLOGY, 10. | |
| Rivista: | ||
| Digital Object Identifier (DOI): | http://dx.doi.org/10.3389/fonc.2020.00734 | |
| Abstract: | The world is facing a new pandemic caused by a novel beta coronavirus (COVID 19), which causes severe respiratory coronavirus syndrome (SARS-CoV-2). Unfortunately, there are currently no US Food and Drug Administration (FDA) approved medications for the treatment of COVID-19 patients. High mortality rates in frail patients is a notable feature of the virus registered since the onset of COVID-19 pandemic. Above all, elderly patients or those with underlying chronic illnesses and compromised immune system are most at risk (1). Thus, the consideration is that the possible coexistence, in the same individual, of a cancer diagnosis and a COVID-19 infection could generate a synergistic negative prognostic effect. | |
| Settore Scientifico Disciplinare: | Settore MED/06 - Oncologia Medica | |
| Appare nelle tipologie: | 1.01 Articolo in rivista |
File in questo prodotto:
| File | Descrizione | Tipologia | Licenza | |
|---|---|---|---|---|
| COVID-19 Infection in Cancer Patients_ How Can Oncologists Deal With These Patients.pdf | N/A | Open Access Visualizza/Apri |
Copyright © 2021